ERBB2 and breast cancer: In addition, in the exploration of intensive adjuvant chemotherapy strategy, neratinib can improve the iDFS of HER-2 positive early BC patients, reduce the risk of recurrence, and benefit more significantly in HER-2 positive and HR positive BC patients(Chan et al. 2021).